Enzalutamide
Brand name: Xtandi
Rank #15 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$985.0M
Total Cost
72,710
Total Claims
$985.0M
Total Cost
2,280
Prescribers
$14K
Cost per Claim
3,604
Beneficiaries
73,470
30-Day Fills
$432K
Avg Cost/Provider
32
Avg Claims/Provider
Share of Medicare Part D Spending
0.36%
of total Medicare Part D spending
$985.0M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $985.0M total
🔎 Data Overview
Ranked #15 out of 500 drugs tracked by total cost. Enzalutamide represents a significant portion of Medicare drug spending.
At $13,547 per prescription, this is a high-cost medication. Expensive drugs drive Medicare spending growth and create access challenges for patients with coverage gaps.
Average cost of $432,008 per prescriber suggests this drug may be concentrated among specialists. High per-provider spending can sometimes indicate inappropriate prescribing or overly aggressive use.
Average cost of $273,302 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Enzalutamide
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Sukumar Ethirajan | Hematology | Overland Park, KS | 704 | $10.4M |
| 2 | Geoffrey Bisignani | Urology | Latrobe, PA | 449 | $6.2M |
| 3 | Stewart Landau | Urology | American Fork, UT | 334 | $4.8M |
| 4 | Jim Hsiang | Radiation Oncology | Corpus Christi, TX | 338 | $4.8M |
| 5 | Zachary Reardon | Urology | Mobile, AL | 306 | $4.3M |
| 6 | Mark Delworth | Urology | Blue Ash, OH | 322 | $4.3M |
| 7 | Clara Hwang | Medical Oncology | Detroit, MI | 343 | $4.3M |
| 8 | Steven Jensen | Urology | Saginaw, MI | 266 | $3.7M |
| 9 | Kevin Courtney | Medical Oncology | Dallas, TX | 246 | $3.3M |
| 10 | Susan Sargent | Nurse Practitioner | Rochester, NY | 272 | $3.3M |
| 11 | John Finnie | Hematology-Oncology | Saint Louis, MO | 243 | $3.2M |
| 12 | Edward Ellison | Urology | Coeur D' Alene, ID | 218 | $3.1M |
| 13 | Sheela Tejwani | Hematology-Oncology | Detroit, MI | 245 | $3.1M |
| 14 | Theodore Affue | Urology | El Centro, CA | 202 | $3.0M |
| 15 | Lynn Mastrianni | Nurse Practitioner | New Haven, CT | 218 | $2.9M |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 12 | Sacubitril/Valsartan (Entresto) | $1.30B | 1,220,812 |
| 13 | Bictegrav/Emtricit/Tenofov Ala (Biktarvy) | $1.29B | 310,738 |
| 14 | Etanercept (Enbrel Sureclick) | $1.12B | 145,737 |
| 15 | Enzalutamide (Xtandi) | $985.0M | 72,710 |
| 16 | Mirabegron (Myrbetriq) | $927.5M | 1,407,073 |
| 17 | Tirzepatide (Mounjaro) | $877.9M | 680,457 |
| 18 | Ibrutinib (Imbruvica) | $875.8M | 56,368 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology